In the future, the role of gefitinib-induced STAT3-Akt activation loop needs to be further tested among the NSCLC cells with different EGFR statuses, which will provide deeper insights into our knowledge of drug resistance in NSCLC and provide valuable information to optimize anti-tumor therapy in lung cancer patients. Here, AKT1 is linked to non-small cell lung carcinoma.